1. Market Research
  2. > Pharmaceutical
  3. > Therapy
  4. > Oncology Market Trends
Global Cancer Vaccine Market & Clinical Trials Outlook 2028

Global Cancer Vaccine Market & Clinical Trials Outlook 2028

  • July 2022
  • 600 pages
  • ID: 6293294
  • Format: PDF
  • Kuick Research

Summary

Table of Contents

Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights:

• Global and Regional Market Size Insight 2022 Till 2028
• Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till 2028
• Cancer Vaccine Market Insight & Forecast By 10 Different Cancers 2022 Till 2028
• Approved Cancer Vaccines Patent, Price, & Dosage Analysis
• Insight On More Than 350 Cancer Vaccines in Clinical Trials
• Cancer Vaccines Trials Insight By Company, Country and Indication
• Insight On More Than 20 Cancer Vaccines Commercially Available In Market

The use of vaccines for the prevention of infectious disease represents one of the greatest achievements in modern medicine. Owing to their advantages, research studies have also focused to explore the potential of vaccines in the prevention or management of chronic diseases including cancer. Cancer vaccine represents unique approach to cancer therapy which alters the interaction of the host and the tumor, enlisting the patient’s tumor response to attack cancer cells. Further, the immunologic memory associated with the administration of vaccines also gained the interest of researchers to invest in this segment.

Till date, both therapeutic as well as preventive cancer vaccines have gained entry into the global market. Several cancer vaccines including Gardasil, Gardasil 9, Cecolin, or Cervarix have been approved to prevent HPV infection which target high risk HPV strains responsible for nearly all cervical cancers and are also linked to some throat, anal, and other cancers. In contrast, Provenge was the first therapeutic vaccine globally approved in 2010 for the management of prostate cancer. Apart from this, CemaVax, Riavax, and Vaxira have also been approved for the management of non-small cell lung cancer and pancreatic cancer. The entrance of vaccines has shown to greatly transform the paradigm of cancer treatment.

Currently, the pipeline of cancer vaccine is highly crowded which are increasingly reporting encouraging success in clinical trials across wide range of cancers. Several vaccines are also awaiting marketing approval or commercialization. For instance, US FDA is currently reviewing BLA application for N-803 plus Bacillus Calmette-Guérin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer. Apart from this, Cervac has been approved in India and is expected to be available in the market soon. The presence of wide range of clinical pipeline products indicates strong future presence of the market.

With the continuous research and development activities in this domain, scientists have also developed other enhanced platforms for vaccine development including mRNA vaccines, personalized neoantigen cancer vaccines, stem cells, and others. Although these are present in early stages of clinical development, these represent huge potential across wide range of cancers. Further, the market will also experience growth with the introduction of artificial intelligence algorithms which aid in the precise detection of neoantigens and also factor the early development of companies. Several top players in the market has utilized machine learning to develop their proprietary artificial intelligence algorithm for the characterization of neoantigens and ultimately developing personalized neoantigen cancer vaccines.

In last few years, pharmaceutical companies have also entered into collaboration with artificial intelligence players to develop potential cancer vaccines. For instance in 2022, CureVac entered into research and option agreement with myNEO which will aim to identify specific antigens found on the surface of tumors for the development of vaccines. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit strong immune response. Apart from this, myNEO also collaborated with Abera Bioscience to develop personalized cancer vaccines. Other key players in the global market are Argos Therapeutics, Nykode Therapeutics, Merck, Regeneron, GlaxoSmithKline, CureVac, Dendreon, Sanofi, and OSE Immunotherapeutics.

As per our report findings, the global cancer vaccine market is expected to surpass US$ 15 Billion by 2028. The significant increase in the growth of market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination. Apart from this, several investigational cancer vaccines have progressed towards late stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028

  • $ 3900
  • June 2022
  • 1320 pages

Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights: • Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028 • Combination ...

  • World
  • Cancer Immunotherapy
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on